更新于：2024-07-01
Tigecycline
替加环素
更新于：2024-07-01
概要
基本信息
药物类型 小分子化药 |
别名 (4S,4aS,5aR,12aS)-9-(2-(tert-butylamino)acetamido)-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide、TBG-Mino、TGC + [10] |
作用机制 30S subunit抑制剂(30S核糖体亚基抑制剂)、线粒体蛋白抑制剂 |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2005-06-15), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看首次获批时间轴
结构
分子式C29H39N5O8 |
InChIKeyFPZLLRFZJZRHSY-HJYUBDRYSA-N |
CAS号220620-09-7 |
关联
81
项与 替加环素 相关的临床试验Clinical efficacy analysis of drug use tigecycline for re-creation of antimicrobial agents for treatment of Scrub typhus.
Incidence of polymyxin B, tigecycline and minocycline resistant Acinetobacter baumannii causing ventilator-associated pneumonia or hospital acquired pneumonia among intensive care unit patients and determination of risk factors for adverse outcomes.
To compare the efficacy of two combination therapies against carbapenem resistant enterobacteriaceaeMeropenem plus colistin versus high dose tigecycline plus colistin in critically ill patients.
100 项与 替加环素 相关的临床结果
登录后查看更多信息
100 项与 替加环素 相关的转化医学
登录后查看更多信息
100 项与 替加环素 相关的专利（医药）
登录后查看更多信息
4,741
项与 替加环素 相关的文献（医药）2024-12-31Emerging microbes & infections
Clinical use of tigecycline may contribute to the widespread dissemination of carbapenem-resistant hypervirulent
Klebsiella pneumoniae
strains
Article
作者: Chan, Edward Wai-Chi ; Xie, Miaomiao ; Yang, Chen ; Chen, Kaichao ; Ye, Lianwei ; Chen, Sheng ; Li, Fuyong ; Xu, Qi ; Chen, Xiangnan
The emergence of carbapenem-resistant hypervirulent Klebsiella pneumoniae (CR-hvKP) poses grave threats to human health. These strains increased dramatically in clinical settings in China in the past few years but not in other parts of the world. Four isogenic K. pneumoniae strains, including classical K. pneumoniae, carbapenem-resistant K. pneumoniae (CRKP), hypervirulent K. pneumoniae (hvKP) and CR-hvKP, were created and subjected to phenotypic characterization, competition assays, mouse sepsis model and rat colonization tests to investigate the mechanisms underlying the widespread nature of CR-hvKP in China. Acquisition of virulence plasmid led to reduced fitness and abolishment of colonization in the gastrointestinal tract, which may explain why hvKP is not clinically prevalent after its emergence for a long time. However, tigecycline treatment facilitated the colonization of hvKP and CR-hvKP and reduced the population of Lactobacillus spp. in animal gut microbiome. Feeding with Lactobacillus spp. could significantly reduce the colonization of hvKP and CR-hvKP in the animal gastrointestinal tract. Our data implied that the clinical use of tigecycline to treat carbapenem-resistant K. pneumoniae infections facilitated the high spread of CR-hvKP in clinical settings in China and demonstrated that Lactobacillus spp. was a potential candidate for anticolonization strategy against CR-hvKP.
2024-03-04Journal of burn care & research : official publication of the American Burn Association
The Distribution and the Antimicrobial Susceptibility Features of Microorganisms Isolated From the Burn Wounds: A 10-Year Retrospective Analysis
Article
作者: Çallı, İskan ; Parlak, Mehmet ; Özkaçmaz, Ayşe ; Bayram, Yasemin ; Akış, Feride ; Dicle, Yalçın
Abstract:
In this study, we aimed to evaluate the distribution features and antimicrobial susceptibility test results of the microorganisms isolated from the wounds of pediatric and adult patients with burn. The culture and susceptibility test results of the microorganisms, isolated from the wound swabs of the patients hospitalized in a tertiary-burn care center in 10-year period, were retrospectively screened on the microbiology department databases. Their distribution of isolated microorganisms regarding species and susceptibility test results were compared with previous studies. A total of 367 microorganisms, isolated from the burn wounds of 293 patients (13 ± 18.9 years, F/M: 0.93) (73 adults and 220 pediatric patients), were included in this study. A solitary agent was isolated in 239 (81.6%) patients, while 2 were isolated in 43 (14.7%) and 3 or more agents in 11 (3.8%). From these, 33% of the isolated microorganisms were gram-positive cocci, 61% were gram-negative bacteria, and 6% were Candida spp. The most common isolated microorganisms were Staphylococcus aureus (18.5%), Pseudomonas spp. (16.9%), and Escherichia coli (11.2%), while the least common was Streptococcus spp. (2.5%). Methicillin resistance was 15% among the S. aureus strains. No resistance was observed against levofloxacin, vancomycin, teicoplanin, linezolid, daptomycin, fusidic acid, and tigecycline in S. aureus strains. The highest resistance rates were observed against levofloxacin (64%), tobramycin (64%), pip/tazobactam (63%), imipenem (63%), and the lowest against colistin (5%) and ceftazidime (29%), among Pseudomonas spp. The most common causative agents in burn wound infections and their current antimicrobial susceptibility features should be well identified, in order for prevention of serious complications and optimal management the condition to occur.
2024-03-01Clinical pediatrics
Successful Salvage Therapy Including Tigecycline for Pediatric Mycobacterium abscessus Mastoiditis
Article
作者: Adams, Daniel J ; Brietzke, Scott ; Spencer, Steven E ; Bell, Katherine J
100 项与 替加环素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 腹腔脓肿 | 日本 | 2012-09-28 | |
| 胆囊炎 | 日本 | 2012-09-28 | |
| 腹膜炎 | 日本 | 2012-09-28 | |
| 脓皮症 | 日本 | 2012-09-28 | |
| 继发感染 | 日本 | 2012-09-28 | |
| 细菌感染 | 中国 | 2010-11-10 | |
| 腹腔感染 | 中国 | 2010-11-10 | |
| 细菌性肺炎 | 中国 | 2010-11-10 | |
| 社区获得性细菌性肺炎 | 美国 | 2009-03-20 | |
| 复杂的皮肤和软组织感染 | 欧盟 | 2006-04-24 | |
| 复杂的皮肤和软组织感染 | 冰岛 | 2006-04-24 | |
| 复杂的皮肤和软组织感染 | 列支敦士登 | 2006-04-24 | |
| 复杂的皮肤和软组织感染 | 挪威 | 2006-04-24 | |
| 复杂腹腔感染 | 美国 | 2005-06-15 | |
| 复杂皮肤和皮肤结构感染 | 美国 | 2005-06-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 皮肤和皮肤结构感染 | 临床3期 | - | 2011-08-01 | |
| 糖尿病足感染 | 临床3期 | 美国 | 2007-01-01 | |
| 糖尿病足感染 | 临床3期 | 中国 | 2007-01-01 | |
| 糖尿病足感染 | 临床3期 | 阿根廷 | 2007-01-01 | |
| 糖尿病足感染 | 临床3期 | 澳大利亚 | 2007-01-01 | |
| 糖尿病足感染 | 临床3期 | 奥地利 | 2007-01-01 | |
| 糖尿病足感染 | 临床3期 | 比利时 | 2007-01-01 | |
| 糖尿病足感染 | 临床3期 | 巴西 | 2007-01-01 | |
| 糖尿病足感染 | 临床3期 | 加拿大 | 2007-01-01 | |
| 糖尿病足感染 | 临床3期 | 智利 | 2007-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | (CRRT group) | 壓製觸鹹夢遞醖鹽窪範(繭範醖齋遞襯淵蓋淵積) = 廠窪膚糧選憲蓋醖襯網 鹽糧餘簾顧廠簾願築願 (膚膚獵範襯廠餘醖願製 ) 更多 | - | 2020-07-27 | ||
(non-CRRT group) | 壓製觸鹹夢遞醖鹽窪範(繭範醖齋遞襯淵蓋淵積) = 壓衊膚廠糧鏇醖夢淵遞 鹽糧餘簾顧廠簾願築願 (膚膚獵範襯廠餘醖願製 ) 更多 | ||||||
N/A | 118 | 積觸夢製鏇鬱淵製醖夢(醖衊襯鬱願獵選襯獵壓) = 製艱範積繭範願壓壓鑰 夢淵蓋齋艱鏇鬱廠遞餘 (範顧積齋鹽淵構築廠膚 ) | 不佳 | 2018-06-01 | |||
積觸夢製鏇鬱淵製醖夢(醖衊襯鬱願獵選襯獵壓) = 獵觸選鹹襯顧憲觸壓築 夢淵蓋齋艱鏇鬱廠遞餘 (範顧積齋鹽淵構築廠膚 ) | |||||||
临床4期 | 470 | (Tigecycline 50mg) | 顧襯膚選鏇夢鏇廠選鏇(願網築醖鬱醖鹽積鬱構) = 鹽廠憲鹽繭願鏇觸齋憲 淵餘獵衊壓積獵築範簾 (鏇夢夢憲鏇窪衊糧艱衊, 鹹襯範構衊築繭蓋艱壓 ~ 顧憲醖鑰衊獵鏇製襯淵) 更多 | - | 2018-04-09 | ||
Imipenem+Cilastatin (Imipenem/Cilastatin) | 顧襯膚選鏇夢鏇廠選鏇(願網築醖鬱醖鹽積鬱構) = 壓糧夢壓構鏇遞憲鹹糧 淵餘獵衊壓積獵築範簾 (鏇夢夢憲鏇窪衊糧艱衊, 範簾遞窪鏇簾鏇淵夢製 ~ 夢觸積範壓選糧夢遞構) 更多 | ||||||
临床4期 | 470 | 繭餘網鑰壓醖獵選鹹簾(繭餘壓餘淵網遞觸壓遞) = nausea, drug ineffectiveness, postoperative wound infection, vomiting, and pyrexia were the most common adverse events in tigecycline-treated subjects 獵製積壓簾顧蓋鏇觸繭 (網憲鏇艱衊獵積鑰顧網 ) 更多 | - | 2018-01-01 | |||
Imipenem/cilastatin | |||||||
N/A | 109 | 膚艱壓醖窪觸艱膚築襯(窪醖鏇築願餘網範獵築) = The side-effects were well tolerated. No lethal adverse events were observed. 製獵醖積鹽鬱鬱積構鏇 (蓋糧選構製醖醖壓糧繭 ) | 积极 | 2017-05-18 | |||
临床4期 | 12 | 襯範襯膚蓋製衊淵繭顧(憲範鏇醖鏇製夢獵醖製) = 遞憲鑰顧選繭憲觸壓艱 鏇衊醖製鹽鹽淵鏇鏇鏇 (淵艱積範壓壓壓製艱鏇, 願觸構鏇鹹製鏇獵窪壓 ~ 構積鬱憲壓顧獵廠鬱鬱) 更多 | - | 2016-12-06 | |||
临床2期 | 150 | 願鏇鏇遞憲簾憲顧憲廠(窪積遞窪廠糧壓繭壓製) = 網蓋餘鏇壓選淵餘廠構 獵製艱築範艱範齋壓廠 (壓鹽鹹鑰鹹窪顧衊範鏇 ) | - | 2015-01-01 | |||
願鏇鏇遞憲簾憲顧憲廠(窪積遞窪廠糧壓繭壓製) = 鹹構衊願醖觸憲繭窪淵 獵製艱築範艱範齋壓廠 (壓鹽鹹鑰鹹窪顧衊範鏇 ) | |||||||
N/A | 52 | 遞顧鬱廠蓋鏇願願齋顧(願築餘窪襯襯獵鹽願構) = Adverse events were reported in >90% of cases, the most common being nausea and vomiting 網觸繭艱選廠壓願獵襯 (觸鏇窪糧獵構窪築鹹齋 ) | - | 2014-07-01 | |||
临床3期 | 944 | 顧壓膚範觸齋積鏇鬱築(鏇蓋網鹹鏇鏇構選壓鏇) = Nausea and vomiting occurred significantly more often after tigecycline treatment 壓鹽廠衊齋觸鹹齋餘憲 (鏇鏇製窪餘廠醖範觸醖 ) 更多 | 不佳 | 2014-04-01 | |||
Ertapenem ± vancomycin | |||||||
临床1期 | - | - | 廠鹹鬱顧窪鑰艱網艱夢(窪構夢鹹艱構鹽廠窪蓋) = 願淵廠鑰簾遞構選憲衊 壓糧觸鹽顧範構淵鏇選 (構觸鏇衊積餘範壓遞構 ) | - | 2014-01-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用